Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

Sage Therapeutics, Inc. Presents at BofA Securities 2020 Health Care Conference, May-13-2020 01:40 PM Transcript

May 13, 2020 / 05:40PM GMT
Release Date Price: €35.8
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good afternoon, everybody. Thanks for joining us at the Bank of America Health Care Conference. I'm Tazeen Ahmad. I'm one of the senior SMID biotech analysts at the firm. It is my pleasure to have our next presenting company. We have Sage presenting with Chief Executive Officer, Jeff Jonas; as well as Chief Operating Officer, Mike Cloonan. Jeff and Mike, good afternoon. Thanks for joining us today.

Jeffrey M. Jonas
Sage Therapeutics, Inc. - CEO, President & Director

Thanks for having us.

Tazeen Ahmad;Jeffrey M. Jonas
BofA Merrill Lynch, Research Division - VP;Sage Therapeutics,

So we'll try to keep this as close as possible to what we ask on our face-to-face meetings. But we usually ask companies to give a 2-minute summary for anyone who may not be as familiar with Sage, about the genesis of the company and some of your recent accomplishments, and then we can go from there about some of the upcoming catalysts to expect.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot